Sljedeći

Auto Play

Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL

2 Pogledi • 07/14/23
Udio
Ugraditi
administrator
administrator
Pretplatnici
0

In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…

Prikaži više
0 Komentari sort Poredaj po
Komentari na Facebooku

Sljedeći

Auto Play